Chemical Property of Pantoprazole
Chemical Property:
- Appearance/Colour:almost white solid
- Vapor Pressure:9.37E-14mmHg at 25°C
- Melting Point:139-140oC, decomposes
- Refractive Index:1.642
- Boiling Point:586.9 °C at 760 mmHg
- PKA:pKa1 3.92; pKa2 8.19(at 25℃)
- Flash Point:308.7 °C
- PSA：105.54000
- Density:1.51 g/cm3
- LogP:3.75000
- Storage Temp.:Inert atmosphere,Store in freezer, under -20°C
- Solubility.:Chloroform (Slightly), Methanol (Slightly, Heated, Sonicated)
- XLogP3:2.4
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:9
- Rotatable Bond Count:7
- Exact Mass:383.07513347
- Heavy Atom Count:26
- Complexity:490
- Purity/Quality:
-
99%, *data from raw suppliers
Pantoprazole *data from reagent suppliers
Safty Information:
- Pictogram(s):
Xn
- Hazard Codes:Xn
- Statements:
20/21/22-37/38-41-48
- Safety Statements:
22-26-36/37/39-45
- MSDS Files:
-
SDS file from LookChem
Useful:
- Drug Classes:Antiulcer Agents
- Canonical SMILES:COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC
- Recent ClinicalTrials:Neuro-immune Interactions and PPI
- Recent EU Clinical Trials:AN EXPLORATORY, MULTICENTER, RANDOMIZED, DOUBLE BLIND STUDY OF CLINICAL OUTCOMES, TOLERABILITY, AND SAFETY OF 2 DOSES OF ORAL PANTOPRAZOLE IN PEDIATRIC PARTICIPANTS AGED 1 TO 11 YEARS AND 12 TO 17 YEARS WHO REQUIRE MAINTENANCE THERAPY FOR HEALED EROSIVE ESOPHAGITIS
-
Description
Pantoprazole, an irreversible proton pump inhibitor, reached its first market
worldwide in Germany for acute treatment of gastric and duodenal ulcers and
gastroesophageal reflux disease. Proton pump inhibitors are more effective than
other strategies in inhibiting acid secretion since they function at the final step of
acid production, therefore, provide superior symptom relief and healing in all acid
related diseases. As the third substituted benzimidazole proton pump inhibitor
marketed, pantoprazole not only has superior ulcer-preventing effect but also is
more potent than omeprazole in healing acetic acid-induced gastric and duodenal
ulcers with extremely low acute toxicity. The mechanism of action for this class of
compounds has been suggested to be mediated via the protonated form of the
molecule which selectively reacts with cysteines present on the extracytoplasmic
face of the enzyme to form covalent disulfide bonds.
-
Uses
proton pump inhibitor, gastric acid release inhibitor, antiulcer
-
Therapeutic Function
Antiulcer
-
Clinical Use
Pantoprazole
-
Drug interactions
Potentially hazardous interactions with other drugs
Anticoagulants: effect of coumarins possibly
enhanced.
Antifungals: absorption of itraconazole and
ketoconazole reduced; avoid with posaconazole.
Antivirals: concentration of atazanavir and rilpivirine
reduced - avoid; concentration of raltegravir and
saquinavir possibly increased - avoid.
Clopidogrel: possibly reduced antiplatelet effect.
Cytotoxics: possibly reduced excretion of
methotrexate; avoid with dasatinib, erlotinib and
vandetanib; possibly reduced lapatinib absorption;
possibly reduced absorption of pazopanib.
Ulipristal: reduced contraceptive effect, avoid with
high dose ulipristal.
